Completed

NCT Number: NCT01503476

Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance

Study Hypothesis:

This study is designed as an integral part of the development of new or improved features or components of the Bravo® pH Monitoring System and may serve verification and validation purposes The study population will include a group of healthy volunteers (Group A) and a group of symptomatic patients with known or suspected gastroesophageal reflux disease (Group B).

Group A: Healthy volunteers will not undergo invasive procedure. These volunteers may be asked to carry the capsule and\\or Bravo Recorder. These procedures will serve to evaluate different technical matters such as human interface, ergonomic aspects and communication performances of the system Group B: Symptomatic patients will undergo invasive procedure, including Bravo capsule delivery, positioning and attachment. Confirmation of capsule attachment may be done by endoscopically.

These procedures will serve to evaluate overall system performance in actual clinical setup, for instance: Bravo Recorder performance including communication quality, human interface and similar, ergonomics of delivery device, pH Capsule performance, etc.

Subjects from both study groups as well as physician may be asked to provide feedback on the procedure and/or document their activities during the procedure.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gastro Esophageal Reflux Disease Deglutition Disorders Digestive System Diseases Esophageal Diseases Esophageal Motility Disorders Gastroesophageal Reflux Gastrointestinal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Bikur Holim medical center

Jerusalem, Israel

About this study

Up to a total of 220 subjects will participate in this study. The study will include two separate population groups. Group A of up to 170 healthy volunteers and Group B of up to 50 symptomatic patients with known or suspected gastro esophageal reflux disease.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subject age ≥ 18 years old
Subject received an explanation about the nature of the study and agrees to provide written informed consent.

Group A (healthy volunteers) Only

Subject is an healthy volunteer

Group B (symptomatic patients) Only 1. The subject was referred for pH monitoring procedure to detect acid reflux for at least one of the following reasons:

Burning substernal chest pain (heartburn)
Regurgitation of food or stomach contents
Dysphagia
Epigastric pain
Non-erosive reflux disease (NERD)

Exclusion criteria

Group A and B-

Subject has a cardiac pacemaker or other implanted electromedical device.
Subject has any condition, which precludes compliance with study and/or device instructions.
Women who are either pregnant or nursing at the time of screening, or are of child-bearing potential and do not practice medically acceptable methods of contraception.
Subject suffers from life threatening conditions
Subject currently participating in another clinical study which may interfere with study objectives, per physician discretion

Additional exclusion criteria for Group B only

Subject has prior abdominal surgery other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator
Subject is schedule to undergo MRI examination within 30 days from pH monitoring procedure.
Subject has known bleeding diathesis, strictures, severe esophagitis, varices and or obstructions -

Treatment and study plan

Bravo® pH Monitoring System

Device

Bravo pH monitoring

Other names: pH monitoring

Primary outcomes

Percentage of data samples transmitted by the capsule and successfully received by the receiver (e.g. percent of missed samples and percent of corrupted samples)

Time frame: up to 96 hours

Percentage of data samples in healthy volunteers and patients transmitted by capsule and successfully received by the receiver (e.g. percent of missed samples and percent of corrupted samples)

Sponsors and collaborators

Lead sponsor

Medtronic - MITG

Industry

Registry information

Official study title

RD-40 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance

Important dates

Study start: 2012
Primary completion: 2016
Study completion: 2016
First posted: Jan 4, 2012
Registry last updated: Jul 31, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed